AIHTA - Publications - Search - Browse by Person
Number of items: 88.

Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.

Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.

Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.

Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.

Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.

Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11.

Grössmann, N. (2021): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Update February 2021. Oncology Fact Sheet Nr. 13.

Grössmann, N. and Wild, C. (2020): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003.

Wolf, S. and Grössmann, N. (2020): Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble). Decision Support Document 123.

Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.

Grössmann, N. (2021): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 15.

Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update February 2021. Oncology Fact Sheet Nr. 16.

Grössmann, N. (2021): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 17.

Grössmann, N. (2021): Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Update February 2021. Oncology Fact Sheet Nr. 18.

Grössmann, N. (2021): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 19.

Grössmann, N. (2021): Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL). Oncology Fact Sheet Nr. 44.

Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.

Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.

Grössmann, N. (2021): Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 22.

Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.

Grössmann, N. (2021): Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 24.

Wolf, S. and Grössmann, N. (2020): Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria. HTA-Projektbericht 129.

Grössmann, N. (2021): Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL). Update February 2021. Oncology Fact Sheet Nr. 25.

Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.

Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.

Grössmann, N. (2020): Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Update February 2021. Oncology Fact Sheet Nr. 28.

Grössmann, N. (2021): Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 29.

Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.

Grössmann, N. (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021. Oncology Fact Sheet Nr. 31.

Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.

Grössmann, N. (2021): Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis. Update April 2021. Oncology Fact Sheet Nr. 33.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.

Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Update April 2021. Oncology Fact Sheet Nr. 35.

Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.

Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.

Grössmann, N. (2021): Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Oncology Fact Sheet Nr. 38.

Grössmann, N. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 39.

Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.

Grössmann, N. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Oncology Fact Sheet Nr. 41.

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Oncology Fact Sheet Nr. 42.

Grössmann, N. (2021): Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM). Oncology Fact Sheet Nr. 43.

Grössmann, N. (2021): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 45.

Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Oncology Fact Sheet Nr. 46.

Grössmann, N. (2021): Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Oncology Fact Sheet Nr. 47.

Grössmann, N. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Oncology Fact Sheet Nr. 48.

Grössmann, N. (2021): Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Oncology Fact Sheet Nr. 49.

Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Oncology Fact Sheet Nr. 50.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

Grössmann, N. (2016): Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM). DSD: Horizon Scanning in Oncology 63.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

Wild, C. and Grössmann, N. (2019): FoundationOne®CDx: genetic profiling of solid tumours. Rapid Assessment 014.

Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.

Grössmann, N. and Wild, C. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 25th Prioritisation – 4th quarter 2015. HSO: 25th Prioritisation.

Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.

Grössmann, N. (2020): Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL. Oncology Fact Sheet Nr. 3.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Grössmann, N. (2016): Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy. DSD: Horizon Scanning in Oncology 59.

Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.

Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Update July 2020. Oncology Fact Sheet Nr. 4.

Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.

Rosian, K. and Fischer, S. and Grössmann, N. (2018): Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety. HTA-Projektbericht 105.

Grössmann, N. (2016): Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion. DSD: Horizon Scanning in Oncology 62.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Robausch, M. and Grössmann, N. (2020): Health Services Research in Oncology. Part I: End-of-Life Care . HTA-Projektbericht 127.

Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

Grössmann, N. and Wolf, S. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 29th Prioritisation – 4th quarter 2016.. HSO: 29th Prioritisation.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 . HSO: 27th Prioritisation.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 28th Prioritisation – 3rd quarter 2016. HSO: 28th Prioritisation.

Fuchs, S. and Grössmann, N. and Eckhardt, H. and Busse, R. and Wild, C. (2018): PET/PET-CT Evidence for need based planning in Germany and Austria. HTA-Projektbericht 77/ Update 2018.

Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Grössmann, N. and Wild, C. (2016): Horizon Scanning in Oncology: Results of the 26th Prioritisation – 1st quarter 2016. HSO: 26th Prioritisation.

Grössmann, N. and Baumann, M. (2016): Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). DSD: Horizon Scanning in Oncology 57.

Baumann, M. and Grössmann, N. (2016): Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 58.

Grössmann, N. (2016): Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL). DSD: Horizon Scanning in Oncology 60.

Grössmann, N. and Wolf, S. (2018): Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018. HSO: 34th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

This list was generated on Tue Jun 22 05:00:48 2021 CEST.